Policies on reporting clinical trials and publishing supplements

Publisher Website
Google Scholar
Abstract
To make Neurology as useful as possible to authors and clinicians, we will expedite publication of important clinical trials (see preceding editorial) and publish well-designed and conducted clinical trials regardless of the outcome of the study. Journals have sometimes had a bias toward publishing "positive" (regarding therapeutic benefit) studies while relegating "negative" studies to appear as abstracts or to less available venues. "Positive" studies with methodologic deficiencies have been prominently published, while "negative" studies with more methodologic rigor have not. We will focus on publishing more rigorously designed studies, specifically those using a control group, randomization, and a method of blinding, instead of publishing studies with weaker designs. Uncontrolled, nonrandomized, unblinded studies will be considered for publicationas Brief Communications or Clinical/Scientific Notes but will rarely be appropriate for publication as full-length articles. Such …

This publication has 1 reference indexed in Scilit: